A new step towards targeting tau

In The Lancet Neurology, Adam Boxer and colleagues2 report the results of a randomised, double-blind, placebo-controlled, multiple ascending dose phase 1b trial, to investigate the safety and tolerability of BIIB092, a humanised monoclonal antibody targeting tau at its N-terminus, in patients with p...

Full description

Saved in:
Bibliographic Details
Published in:Lancet neurology 2019-06, Vol.18 (6), p.517-518
Main Authors: Corvol, Jean-Christophe, Buée, Luc
Format: Article
Language:English
Subjects:
Alzheimer's disease
Animal models
Clinical trials
Drug dosages
Immunotherapy
Monoclonal antibodies
N-Terminus
Neurodegenerative diseases
Paralysis
Pharmacodynamics
Progressive supranuclear palsy
Tau protein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In The Lancet Neurology, Adam Boxer and colleagues2 report the results of a randomised, double-blind, placebo-controlled, multiple ascending dose phase 1b trial, to investigate the safety and tolerability of BIIB092, a humanised monoclonal antibody targeting tau at its N-terminus, in patients with progressive supranuclear palsy. Over the past decade, three large clinical trials done in individuals with progressive supranuclear palsy did not demonstrate clinical efficacy.4–6 Because none of these trials provided evidence of a pharmacodynamic effect, the question remains as to whether the negative outcomes were related to erroneous targeting or to target engagement failure. [...]the majority of tau in the Alzheimer's disease brain is truncated, mostly at the N-terminus.9 Therefore, targeting the mid-region of tau might be an alternative strategy—a strategy that has shown some efficacy in animal models.10 Ongoing clinical trials of antibodies and vaccine strategies targeting different species of tau in progressive supranuclear palsy, Alzheimer's disease, and other tauopathies will hopefully provide a clearer picture of the efficacy of anti-tau therapies.
ISSN:1474-4422
1474-4465
DOI:10.1016/S1474-4422(19)30161-9